ADTX

Aditxt is a pre-commercial biotech that management itself flags as a going-concern risk, and the numbers are catastrophic. FY2025 revenue collapsed to $3.19K — down 97.6% YoY and effectively zero — against a net loss of $43.1M and operating cash outflow of $25.7M. With only $3.20M of cash on hand, the company is burning roughly eight times its liquidity per year; the MD&A confirms it has 'generated no significant revenue from commercial sales to date' and the entire value proposition rests on ADI-100, a preclinical immune-modulation candidate whose first human trial (Stiff Person Syndrome, 10-20 patients) is only 'expected to get underway in 2026' pending IRB and FDA clearance. This is a binary, multi-year clinical bet with no product, no meaningful revenue, and no margin of safety.

The capital structure is the more immediate killer for equity holders. The Risk Factors are explicit that the company 'may need to raise additional funding' on terms 'dilutive to you,' that it has already 'issued a significant number of shares of convertible preferred stock and warrants,' and that continued Nasdaq listing is in question. The financials show the mechanism at work: a diluted EPS of -$1,153.83 and a 22% YoY drop in share count signal reverse-split-and-reissue churn, while accumulated deficit has ballooned to -$210M. The nominal equity increase to $5.61M and the current ratio problem (current liabilities $12.2M vs. current assets $3.82M) confirm the balance sheet only survives by continuously selling stock into the market — structural downward pressure on an already sub-penny price.